140 related articles for article (PubMed ID: 35265947)
1. Expression of NKX3.1, Prostatic Specific Antigen and Prostatic Specific Alkaline Phosphatase in Cytology Specimens of Metastatic Prostatic Carcinoma.
Wang M; Abi-Raad R; Adeniran AJ; Cai G
J Clin Transl Pathol; 2021 Dec; 1(1):16-20. PubMed ID: 35265947
[TBL] [Abstract][Full Text] [Related]
2. Performance of different prostate specific antibodies in the cytological diagnosis of metastatic prostate adenocarcinoma.
Jia L; Jiang Y; Michael CW
Diagn Cytopathol; 2017 Nov; 45(11):998-1004. PubMed ID: 28888085
[TBL] [Abstract][Full Text] [Related]
3. NKX3.1 as a marker of prostatic origin in metastatic tumors.
Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
[TBL] [Abstract][Full Text] [Related]
4. NKX3.1 and PSMA are sensitive diagnostic markers for prostatic carcinoma in bone metastasis after decalcification of specimens.
Huang H; Guma SR; Melamed J; Zhou M; Lee P; Deng FM
Am J Clin Exp Urol; 2018; 6(5):182-188. PubMed ID: 30510970
[TBL] [Abstract][Full Text] [Related]
5. Skene's Gland Derivatives in the Female Genital Tract and Cervical Adenoid Basal Carcinoma are Consistently Positive With Prostatic Marker NKX3.1.
Hawari R; Fernandes L; Park KJ; McCluggage WG
Int J Gynecol Pathol; 2021 Jul; 40(4):400-407. PubMed ID: 33021555
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
Kristiansen I; Stephan C; Jung K; Dietel M; Rieger A; Tolkach Y; Kristiansen G
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28555048
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of NKX 3.1 and HOXB 13 in bone metastases originating from prostatic carcinoma among the Egyptian males.
Abouhashem NS; Salah S
Pathol Res Pract; 2020 Oct; 216(10):153221. PubMed ID: 32979741
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry in diagnostic surgical pathology of the prostate.
Hameed O; Humphrey PA
Semin Diagn Pathol; 2005 Feb; 22(1):88-104. PubMed ID: 16512601
[TBL] [Abstract][Full Text] [Related]
9. Utility of NKX3.1 Immunostaining in the Detection of Metastatic Prostatic Carcinoma on Fine-Needle Aspiration Smears.
Gan Q; Joseph CT; Guo M; Zhang M; Sun X; Gong Y
Am J Clin Pathol; 2019 Sep; 152(4):495-501. PubMed ID: 31175351
[TBL] [Abstract][Full Text] [Related]
10. Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate.
Ellis DW; Leffers S; Davies JS; Ng AB
Am J Clin Pathol; 1984 Mar; 81(3):279-84. PubMed ID: 6199966
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
12. The utility of PSMA and PSA immunohistochemistry in the cytologic diagnosis of metastatic prostate carcinoma.
Bernacki KD; Fields KL; Roh MH
Diagn Cytopathol; 2014 Jul; 42(7):570-5. PubMed ID: 24273068
[TBL] [Abstract][Full Text] [Related]
13. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
14. Correlation between immunohistochemical patterns and serum levels of PSA and PSAP in prostatic pathology: evaluation of 198 prostatic fine needle biopsies.
Vitali A; Ardoino S; Durante P; Ferro MA; Li Causi F; Parodi C; Sanguineti G; Gaffuri M; Paerachino M; Salvadori RP
Anticancer Res; 1994; 14(4A):1503-7. PubMed ID: 7526771
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma.
Kraus TS; Cohen C; Siddiqui MT
Diagn Pathol; 2010 Sep; 5():63. PubMed ID: 20863373
[TBL] [Abstract][Full Text] [Related]
16. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
17. NKX3.1 Expression in Non-Prostatic Tumors and Characterizing its Expression in Esophageal/Gastroesophageal Adenocarcinoma.
Mehreen A; Manjee KG; Paralkar D; Paner GP; Lan T
Adv Anat Pathol; 2024 May; 31(3):202-205. PubMed ID: 38525603
[TBL] [Abstract][Full Text] [Related]
18. Utility of NKX3.1 immunohistochemistry in the differential diagnosis of seminal vesicles versus prostatic tissue in needle biopsy.
Pitra T; Pivovarcikova K; Alaghehbandan R; Compérat EM; Hora M; Rogala J; Slisarenko M; Michal M; Hes O
Ann Diagn Pathol; 2020 Dec; 49():151644. PubMed ID: 33126153
[TBL] [Abstract][Full Text] [Related]
19. Utilization of NKX3.1, P501S, Prostate-Specific Antigen, and Steroidogenic Factor 1 to Distinguish Malignant Leydig Cell Tumor From Metastatic Prostatic Adenocarcinoma to the Testis.
Erak E; Ulbright TM; Epstein J
Arch Pathol Lab Med; 2023 Dec; 147(12):1458-1460. PubMed ID: 36881770
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical Reactivity of Prostate-Specific Markers for Salivary Duct Carcinoma.
Takada N; Nishida H; Oyama Y; Kusaba T; Kadowaki H; Arakane M; Wada J; Urabe S; Daa T
Pathobiology; 2020; 87(1):30-36. PubMed ID: 31865345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
